APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/10/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Olmesartan medoxomil/Amlodipine 20 mg/5 mg film-coated tablets Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine 20 mg/5 mg film-coated tablets

accord healthcare limited - olmesartan medoxomil; amlodipine (as amlodipine besilate ph. eur.) - film-coated tablet - 20/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Olmesartan medoxomil/Amlodipine 40 mg/5 mg film-coated tablets Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine 40 mg/5 mg film-coated tablets

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Olmesartan medoxomil/Amlodipine 40 mg/10 mg film-coated tablets Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

olmesartan medoxomil/amlodipine 40 mg/10 mg film-coated tablets

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

SEVIKAR 20/10 olmesartan medoxomil / amlodipine (as besilate) 20/10 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sevikar 20/10 olmesartan medoxomil / amlodipine (as besilate) 20/10 mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

SEVIKAR 40/5 olmesartan medoxomil / amlodipine (as besilate) 40/5 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sevikar 40/5 olmesartan medoxomil / amlodipine (as besilate) 40/5 mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

SEVIKAR 40/10 olmesartan medoxomil / amlodipine (as besilate) 40/10 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sevikar 40/10 olmesartan medoxomil / amlodipine (as besilate) 40/10 mg tablet blister pack

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/5/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/5/25 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: povidone; pregelatinised maize starch; silicified microcrystalline cellulose; lactose monohydrate; magnesium stearate; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/5/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.